Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non‐Hodgkin lymphoma | Zendy

Ansell Stephen M. | Zendy; Novak Anne J. | Zendy; Ziesmer Steven | Zendy; PriceTroska Tammy | Zendy; LaPlant Betsy | Zendy; Dillon Stacey R. | Zendy; Witzig Thomas E. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non‐Hodgkin lymphoma

Author(s) -

Ansell Stephen M.,

Novak Anne J.,

Ziesmer Steven,

PriceTroska Tammy,

LaPlant Betsy,

Dillon Stacey R.,

Witzig Thomas E.

Publication year - 2009

Publication title -

american journal of hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.456

H-Index - 105

eISSN - 1096-8652

pISSN - 0361-8609

DOI - 10.1002/ajh.21328

Subject(s) - rituximab , follicular lymphoma , medicine , lymphoma , b cell activating factor , oncology , follicular phase , immunology , gastroenterology , antibody , b cell

Serum B‐lymphocyte stimulator (BLyS) levels are elevated in a subset of non‐Hodgkin lymphoma (NHL) patients, particularly those with a family history of B‐cell malignancies or a polymorphism in the BLyS gene. BLyS promotes growth of malignant B‐cells and increased serum BLyS levels are associated with a poor clinical outcome. In this study, BLyS levels were measured before and after 4 weekly doses of rituximab in 30 patients with previously untreated follicular Grade 1 NHL. A significant increase was seen in the serum levels of BLyS ( P = 0.0001) after rituximab therapy. The increase was independent of genetic variability in the BLyS gene. Am. J. Hematol., 2009. © 2008 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research